ASA404 to feature in Novartis Oncology Pipeline Update and at San
Antonio Breast Cancer Symposium
(Thomson Reuters ONE) - London, UK, Cambridge, MA, and Basel, Switzerland: 9 December 2009 -Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that Novartis, itspartner for ASA404, will feature ASA404 in today's Oncology pipelineupdate for investors. A webcast will be available via the Novartiswebsite at www.novartis.comThe update covers recent progress on the ASA404 lung cancerprogramme, notably the completion of enrolment into the ATTRACT-1trial investigating ASA404 as a first-line treatment for non-smallcell lung cancer (NSCLC). Novartis also reiterates its plan to fileASA404 in NSCLC in 2011 and to extend development of ASA404 to breastcancer. The breast cancer programme will include a phase IB/II trialstarting in 2010. This trial will enrol patients receiving first-linetreatment for HER-2 negative metastatic disease and will combineASA404 with taxanes. Additional details are not being made public atthis time, and are expected to be announced at the time the breastcancer trials begin.Preclinical data on ASA404 in breast cancer will be presented thisweek by Novartis scientists at the San Antonio Breast CancerSymposium. A poster entitled "Combination effects following additionof the Tumour-Vascular Disrupting Agent ASA404 (vadimezan) totaxane-containing regimens of trastuzumab and bevacizumab in humanbreast cancer xenograft models" will be presented at the meeting onFriday.Glyn Edwards, Antisoma's CEO, said: "Novartis is running asubstantial development programme for ASA404 in non-small cell lungcancer and we are very pleased to see this extending to HER-2negative metastatic breast cancer, another major cancer indicationwhere there is significant unmet need."Enquiries:Antisoma plc:Glyn Edwards, CEO +44 (0) 203 249 2100Daniel Elger, VP, Marketing & +44 (0) 7909 915 068CommunicationsMark Court/Lisa Baderoon/Catherine Breen +44 (0)20 7466 5000Buchanan CommunicationsBrian Korb +1 646 378 2923The Trout GroupExcept for the historical information presented, certain mattersdiscussed in this statement are forward looking statements that aresubject to a number of risks and uncertainties that could causeactual results to differ materially from results, performance orachievements expressed or implied by such statements. These risks anduncertainties may be associated with product discovery anddevelopment, including statements regarding the company's clinicaldevelopment programmes, the expected timing of clinical trials andregulatory filings. Such statements are based on management's currentexpectations, but actual results may differ materially.About ASA404ASA404 (vadimezan, formerly known as DMXAA and AS1404) is asmall-molecule Tumour-Vascular Disrupting Agent (Tumour-VDA) whichtargets the blood vessels that nourish tumours. The drug wasdiscovered by Professors Bruce Baguley and William Denny and theirteams at the Auckland Cancer Society Research Centre, University ofAuckland, New Zealand. It was in-licensed by Antisoma from CancerResearch Ventures Limited (now Cancer Research Technology), thedevelopment and commercialisation company of the Cancer ResearchCampaign (now Cancer Research UK), in 2001. Worldwide rights to thedrug were licensed to Novartis AG in April 2007; Antisoma has anoption to co-sell ASA404 with Novartis in the United States. Novartisis conducting phase III studies of ASA404 in NSCLC, and also plans toinvestigate the drug's potential as a treatment for metastatic breastcancer.A randomised phase II trial in patients receiving first-linetreatment for NSCLC showed that addition of ASA404 to carboplatin andpaclitaxel chemotherapy improved survival by 5 months. A second,single-arm, phase II trial also reported positive results with ASA404in the same patient group.About AntisomaAntisoma is a London Stock Exchange-listed biopharmaceutical companythat develops novel products for the treatment of cancer. The Companyhas operations in the UK and the US. Please visitwww.antisoma.com for further information about Antisoma.---END OF MESSAGE---This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 09.12.2009 - 08:01 Uhr
Sprache: Deutsch
News-ID 9412
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 422 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ASA404 to feature in Novartis Oncology Pipeline Update and at San
Antonio Breast Cancer Symposium"
steht unter der journalistisch-redaktionellen Verantwortung von
Antisoma plc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
